Picato - direct healthcare professional communication (DHPC)

Ingenol mebutate

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Picato (ingenol mebutate): Suspension of the marketing authorisation due to risk of skin malignancy

Key facts

• Medicine name:
  Picato
• Active substance:
  Ingenol mebutate
• Therapeutic area (MeSH):
  Keratosis, Actinic
• Procedure number:
  EMEA/H/A-20/1489/C/2275/1489
• Regulatory outcome:
  Suspension
• DHPC type:
  • Interim measures
  • Referral - Article 20 procedure
• Human ATC codes:
  D06BX02
• Dissemination date:
  27/01/2020